

12/1/2009

Prognostic Indicators in Head and Neck Oncology including the new 7th edition of the AJCC staging system

Margaret Brandwein-Gensler, MD

Richard V Smith, MD, FACS

Introduction

Head and neck squamous cell carcinoma (HNSCC) represents a number of different diseases each with unique clinical “niche” issues. Clinicopathologic or molecular studies based upon small numbers of patients which group together different anatomic sites and stages are not optimized to address these niche issues and are usually destined to have limited clinical impact. An underlying consideration for any investigation is, “Will this biomarker/indicator add prognostic value beyond known clinical confounders?” Will it retain prognostic significance after model building, which should include confounders such as site, stage, gender, age, and treatment, as well as other factors such as the continuation of smoking, race, HPV status, and resection margin status? Only biomarkers/indicators that remain significantly associated with outcome after regression analysis have the potential for clinical usefulness. The number of confounders requiring consideration will impact the required cohort size to study any biomarker. It is startling how rarely this issue of sample size is mentioned in publications, and often omitted is the acknowledgment that the lack of statistical significance in small studies does not negate the possibility of a significant association.

The goal of this manuscript is to review the recent changes in the 7th edition of the AJCC staging criteria for HNSCC and to focus on some of the validated prognostic indicators for HNSCC. The following focused questions currently facing clinicians will be discussed:

- 1) Which patients with stage I oral SCC will require elective neck dissection?
- 2) Which patients with stage I/II oral/oropharyngeal SCC will fail primary surgical therapy?
- 3) What impact does resection margin status have on outcome?
- 4) Which oropharyngeal carcinomas are HPV+ driven cancers, and thus may be overtreated by current regimens?

I. The 7th AJCC Staging Criteria – General Issues

The recently published 7th AJCC staging criteria¹ contain the following major modifications for head and neck cancers: 1) Staging components for nasopharyngeal carcinoma have shifted 2) Thyroid T1 neoplasia are now subdivided into T1a and T1b, and 3) New staging criteria have been added for mucosal melanoma. A common minor change is the addition of the descriptors “moderately advanced” and “very advanced” to T4a and T4b tumors, respectively, for lip, oral cavity, oropharynx, nasal cavity, laryngeal, major salivary carcinomas and thyroid carcinomas. However the actual anatomic landmarks defining T4a and T4b for each of these anatomic

sites remain the same. Additionally, reporting prognostic factors ('site-specific factors") is recommended for oral and pharyngeal cancers, although not required for staging. These site-specific factors are related to the primary site, i.e. tumor thickness and HPV status, as well as nodal disease, i.e. node size, location/level, and extracapsular spread. Tumor thickness is germane to only small T1 SCC, and expressed in millimeters. It is measured perpendicularly from the surface of the invasive SCC to the deepest area of involvement. This indicator measures both the exophytic and invasive tumor components. In distinction, the indicator of tumor depth of invasion is measured from the level of the mucosal surface to the deepest part of the tumor. Depth of invasion is also germane to only small T1 SCC. With respect to HPV status as a site-specific factor, *there are no recommendations as to the specific method for HPV detection.*

Extracapsular spread has long been recognized as being associated with poorer prognosis, and can be recognized clinically by the presence of a "matted" lymph node mass, fixation to overlying skin, carotid sheath structures, soft tissues, or cranial nerve involvement. Pathologically, extracapsular spread should be classified as either gross (Eg), characterized by tumor apparent to the naked eye beyond the confines of the lymph node capsule, or microscopic (Em), defined as metastatic tumor beyond the lymph node capsule, associated with desmoplasia. No extracapsular spread should be designated as En. The reporting of the following features is also recommended: 1) Histological grade, (although subjectivity is acknowledged), 2) Vascular invasion and 3) Perineural invasion.

a. Changes in Staging for Nasopharyngeal Carcinoma (NPC)

The staging criteria for NPC has become more consolidated. Tumors previously classified as T2a (extension to oropharynx and nasal cavity without parapharyngeal extension) are now classified as T1; consequently, Stage IIA NPC is now Stage I. Tumors previously classified as T2b (parapharyngeal extension – beyond pharyngobairar fascia) are now classified as T2 and Stage IIB NPC is now Stage II. Lastly, bilateral retropharyngeal lymph node metastases, previously classified as N2, are now classified as N1. (Table 1) Histologically, NPC is classified according to the latest WHO criteria (keratinizing, nonkeratinizing, and basaloid). This replaces the previous terminology of WHO I (keratinizing carcinoma), WHO II (transitional cell carcinoma) and WHO III (undifferentiated or lymphoepithelial carcinoma).

b. Changes in Staging for Thyroid Carcinoma

For thyroid neoplasia, T1 tumors are now staged as either T1a (≤ 1 cm) or T1b ($> 1-2$ cm), but the TNM staging groups are not affected. The most significant staging modifier for well-differentiated thyroid cancer (papillary and follicular carcinomas) remains patient age. Patients under 45 with well-differentiated thyroid cancer, any T, any N, and M0 have Stage I disease; while those patients with distant metastases (M1) are classified as Stage II. Patients 45 years of age or older are classified either as Stage I, II, III, or IV by other grouping definitions. Finally, descriptors of solitary (s) versus multifocal (m) tumor have been added to the pathologic staging.

c. New Staging Criteria for Head and Neck Mucosal Melanoma

Primary head and neck MM are rare and aggressive tumors which have not yet had a practical or useful staging system. The new staging criteria reflect the aggressive nature of head neck mucosal melanoma, as all of these tumors are classified as high-stage. (Table 2) Mucosal melanomas are commonly polypoid; T stage criteria are based on the degree of tumor extension, rather than size. Primary tumors are staged as either T3 (mucosal disease), T4a (moderately advanced disease involving deep soft tissue, cartilage, bone, or skin) or T4b (very advanced disease involving brain, dura, skull base, cranial nerves, masticator space, carotid artery, prevertebral space, or mediastinum). Although not specified, it is reasonable to assume that the classification as T4a may be based solely on microscopy. The sinonasal tract is the most common site for head neck mucosal melanoma. A polypoid sinonasal melanoma with only microscopic evidence of nasal septal invasion would then be classified as T4a.

Regional lymph nodes are classified as either NX (cannot be assessed), N0 (no node metastases) or N1 (positive regional nodes). Table 2 demonstrates the combined staging groupings. Additional recommended reported site specific factors are tumor thickness and size, level, and extracapsular spread, with respect to positive nodes.

II. Prognostic Indicators

a. Elective neck dissection for T1cN0 Oral Squamous Carcinoma

Oral squamous cell carcinoma (OSCC) is approached as a primary surgical disease. Cervical lymph node dissection is usually included in the primary surgery for T2/T3/T4 OSCC. What is the optimum treatment for T1 OSCC with clinically N0 (node negative) necks? It is generally accepted that a risk of occult cervical metastases $\geq 20\%$ is an indication for elective neck dissection, and efforts have been centered upon primary

tumor characteristics to assess risk on an individual basis. These factors have included lymphovascular invasion, perineural invasion, tumor depth of invasion, and tumor thickness. If the risk of occult metastases is greater than 20%, what are the risks and benefits of elective neck dissection? There is little local morbidity from this surgical procedure although it does increase operative time. However it is debatable whether elective neck dissection affects long-term survival; comprehensive review of the published clinical data examining this issue is beyond the scope of this manuscript. Patients who are followed closely and develop locoregional recurrence can be adequately treated by salvage surgery if diagnosed early and treated aggressively. Alternatively, elective neck dissection can be viewed as a staging procedure providing prognostic information for locoregional disease-status, adjuvant therapy, and potentially accomplish the same outcomes as salvage neck surgery with far less morbidity.

Yuen et al recently published a randomized clinical trial addressing elective neck dissection for patients with Stage I/II tongue carcinoma and clinical N0 necks.² The necks were treated either by elective dissection (36 patients) or observation (35 patients). Occult metastases were found in 22% of the elective neck dissection group, and the majority (88%) of these patients went on to receive adjuvant radiotherapy. The locoregional recurrence rate was higher in the observational group, 11/35 (31%), as compared to the elective neck dissection group, 2/36 (6%). Most patients in the observation arm who developed locoregional recurrence were successfully salvaged and there were no differences in the 5-year survival rates for either group. They concluded that an advantage of elective neck dissection is that it allows for less extensive surgery (selective neck dissection) as compared to salvage radical neck dissection. There is additional controversy regarding whether patients with pN1 lacking extracapsular spread require adjuvant radiotherapy. As this study has a small number of patients in each group, caution must be maintained in overgeneralizing the results. Additionally, the authors advocated future studies addressing the extent of extracapsular spread and locoregional recurrence.

b. Predictors of Occult Metastases: Tumor Depth of Invasion

Which indicators predict occult metastases to the cervical lymph nodes? Ideally, these indicators should be derived from studies limited to patients with T1 and T2 tumors and cN0 necks, and therefore the inclusion of data from patients with clinically positive lymph nodes possibly skews the results. Optimally, subsites should also be considered independently, as anatomic differences might influence the rate of occult metastases. Occult metastases can be predicted by tumor depth of invasion, tumor thickness, and also tumor pattern of invasion. Tumor depth of invasion is considered a better predictor than tumor thickness.

c. Tumor Depth of Invasion and Tongue SCC

Tumor depth of invasion is an accepted indicator which is significantly associated with occult cervical metastases. Fakhri reported on 70 patients with T1/T2 cN0 tongue SCC and found that a cut-off for depth of invasion of **4mm** was predictive of occult cervical metastases.³ This was the very first study to randomize patients into elective neck dissection and observation arms; however unlike the study by Yuen, no significant differences in disease-free survival were observed between the two treatment groups. This may be due to the inclusion of more T2 patients (66%) as compared to Yuen's randomized trial (39%).² Fukano studied 34 patients with tongue SCC, all stages, but separated out the data for cN0 patients.⁴ No occult metastases were associated with depth of invasion < **3mm**. Occult metastases were found in **6%** of tumors with < **5mm** depth of invasion and **65%** of tumors with depth of invasion \geq **5mm**. Sparano studied 45 patients with T1/T2 cN0 tongue SCC and found a significant cut off at **4mm** for both depth of invasion and tumor thickness.⁵ No occult metastases were found for tumors with < **4mm** depth of invasion and/or tumor thickness, whereas occult metastases were present in **42%** and **41%** of tumors with depth of invasion and tumor thickness \geq **4mm**, respectively. The above studies support a cut-off of **4-5mm** for depth of invasion in tongue SCC. More recently, An et al studied 63 patients with T1/T2 cN₀ tongue SCC.⁶ While this study did not investigate predictors of occult metastases, it did find that a depth of invasion cut-off of 3 mm and/or invasion into intrinsic muscle was associated with regional recurrence. Given these results, and others, the generally accepted tumor depth of \geq **4mm** is commonly used as the major criterion for elective neck dissection in T1N0M0 tongue SCC.

d. Tumor Thickness and Floor of Mouth SCC

Only one study focused on patients with low-stage floor of mouth cancers with cN0 necks. Mohit-Tabatabai reported on 84 patients with T1/T2 cN0 floor of mouth SCC, examining the indicator of tumor thickness.⁷ Occult metastases were found in one of 57 (**2%**) tumors \leq **1.5mm** thick, four of 12 (**33%**) tumors between **1.6** and **3.5mm** thick, and nine of 15 (**60%**) tumors thicker than > **3.5mm**; this supports a cut-off > **1.5mm**. This one study suggests that thinner cancers in the floor of mouth SCC may metastasize, as compared to the tongue. However appropriate validation is lacking, and the same indicators (depth of invasion) should be compared. Suzuki, and Wallwork, studied patients with T1/T2 floor of mouth SCC, however these studies are suboptimal as they included patients with clinically positive lymph nodes which possibly could skew significant cut-off values.^{8,9}

e. Predicting Treatment Failure in Low-stage Oral/Oropharyngeal SCC: Our Risk Model

Patients with Stage I/II oral/oropharyngeal SCC are usually treated with single modality protocols. As many as 25% and 37% of Stage I and Stage II oral cavity cancer patients, respectively, develop locoregional recurrence, suggesting that more aggressive protocols are warranted for a subset of low-stage patients.¹⁰ Offering adjuvant radiotherapy to all low-stage patients would expose a larger subpopulation to unnecessary, harmful toxicities. Therefore the identification of low-stage patients who are at a high risk of disease progression or recurrence would represent a tremendous advantage in the management of this disease, as they could be candidates for targeted administration of multimodality treatment protocols.

Multiparameter histological predictive models have been advocated in Europe since the 1970s. Could these models be used to predict which low-stage patients are at risk for disease-progression? Tumor pattern of invasion at the tumor host interface is a consistent component of these models.¹¹⁻²⁰ Other components have included lymphocytic host response, exophytic versus endophytic growth pattern, mitotic rate, degree of keratinization, and nuclear pleomorphism. Interestingly, perineural invasion, a component of our Risk Model (see below) was never part of these models. Most data supporting associations of perineural invasion with outcome are derived from univariate analyses.²¹ Few studies demonstrate that perineural invasion maintains prognostic significance after multivariable modeling.²²⁻²⁴

Jakobsson's original model evaluated 8 variables in a 4-tiered scoring system. This cumbersome system was modified into a four-variable four-tiered system by Bryne.^{12-14,16} Attempts at validating the Bryne model, and pattern of invasion as a single indicator, however, were not always successful. Problems with the validation studies included small sample size, heterogeneous tumor sites and primary treatment modalities, plus evaluation of different specimen types, as some studies evaluated only biopsies, others only resection specimens, and still others evaluated both biopsies and resection specimens.

We published a novel Risk Model in 2005 that extended previous models and contained unique features.²⁵ The Risk Model classified patients into low-, intermediate-, and high-risk groups, and correlated significantly with locoregional recurrence ($p = 0.0004$) and overall survival ($p = 0.0001$). The greater levels of statistical significance indicated that the performance of our Risk Model was better than the Bryne Model. While the Bryne and Jakobsson models are linear, assigning equal weight to each variable, the Risk Model is non-linear. It groups together non-aggressive patterns of invasion, while assigning greater point value for carcinomas

that spread beyond the main mass (Worst pattern of invasion type 5 - 3 points) as compared to carcinomas forming small islands which remain close to the main tumor (Worst pattern of invasion type 4 - 1 point). Worst pattern of invasion type 5 is unique to our model, describing a tumor phenotype with a dispersed pattern of invasion. We found worst pattern of invasion type 5 in 25% of tumors and it is significantly associated with poorer outcome. Perineural invasion of large nerves (> 1mm diameter) is another unique feature of our model. It is also significantly associated with poorer outcome as compared to small nerve involvement or no perineural invasion. We have recently completed the first validation study on a cohort of 305 patients with primary HNSCC of the oral cavity, oropharynx, and larynx, from three different institutions.²⁶ The median follow-up period for all patients was 27 months. The outcome data confirm that the risk categories are predictive of time to disease progression ($p = 0.0005$), locoregional recurrence ($p = 0.013$), and overall survival ($p = 0.0000$) by Kaplan Meier analysis. Cox regression analysis confirms that the high-risk status is significantly associated with decreased time to disease progression ($p = 0.015$, HR 2.32 95% CI 1.18, 4.58) compared to collapsed intermediate- and low-risk groups. (Table 3)

In response to the original question, it is reasonable to expect that high-risk status confers the same prognostic implications when application is limited to patients with low-stage disease. This has been demonstrated in the above study since the confounder of stage was considered in the regression analysis. However, this first validation study was not powered to demonstrate added predictive value *within* a low-stage cohort. Over 500 Stage I/II patients will need to be assessed to provide adequate power and multi-institutional accrual is underway. However an interim subgroup analysis of low-stage patients ($n = 107$) reveals that high-risk status predicts decreased time to overall survival ($p = 0.0239$) and disease progression ($p = 0.0070$) on univariate analysis. Once the high-risk category has demonstrated predictive value for low-stage patients, widespread application can be advocated as a tool to be used in the development of new treatment protocol.

f. The Prognostic Significance of Resection Margins

The disease-free survival benefit of adequate resection margins been demonstrated in a number of large studies. Using the definition of “tumor cut-through” for positive margins, Byers²⁷ reported on 216 patients, and demonstrated local recurrence rates of **80%** in the positive margin group, compared to **12-18%** in the negative margin group. The definition of ≥ 5 mm for margin adequacy is a common standard, and was used in the following statistically significant studies.²⁸⁻³⁰ Chen reported on 270 patients and demonstrated locoregional

recurrence of **55% versus 17%**, and 5-year disease-free survival of **7% versus 39%**, for inadequate, versus negative margin groups, respectively.²⁸ Loree reported on 303 patients and demonstrated locoregional recurrence of **30% versus 18%**, and 5-year overall survival of **52% versus 60%**, for inadequate, versus negative margin groups, respectively.²⁹ Garzino reported on 245 patients and demonstrated 5-year overall survival of **48% versus 65%**, for inadequate, versus negative margin groups, respectively.³⁰

No study has ever directly compared different margin distances. For instance, is there any benefit in achieving 10mm clearance? McMahon studied 237 patients using a 10mm standard for margin adequacy.²⁴ This study confirmed that resection margin status was associated with local recurrence and disease-specific survival on univariate analysis. Unfortunately, the data presented does not allow for comparison of corresponding outcomes with other centers using a 5 mm clearance standard.

Conversely, some studies fail to demonstrate significant outcome differences relating to resection margin status. Amaral and colleagues studied 188 patients with clinical Stage I/II oral SCC; they found that the disease-free and overall survival rates were unaffected by margin status (5 mm standard).³² Weijers reported on 68 patients, all stages, with oral SCC, and found no significant differences in locoregional recurrence between patient groups for negative (**2/30 or 6.6%**) and close margins (**< 5 mm, 3/38 or 7.9%**), after the exclusion of patients with frankly positive (“cut through”) margins.³³ Similarly, we found no significant differences in locoregional recurrence between patient groups for negative (**28/119, or 23.5%**) and close margins (**< 5 mm, 4/30 or 13%**), after the exclusion of 19 patients with frankly positive (“cut through”) margins.²⁵ The local recurrence rates for patients with inadequate margins in these two studies^{25,33} are better than for the corresponding inadequate margin groups in the previous studies,^{28,29} although the same 5 mm margin standard was used. Why would some “inadequate” resection margins be associated with better outcome than others?

Comparing outcome data by resection margin status across different institutions is extremely complex. In addition to considering the usual confounders (age, gender, site, T and N stage, indications for adjuvant therapy, type of adjuvant therapy, smoking, HPV status), other layers of confounders require consideration such as the method of margin assessment and surgical techniques. It would be reasonable to expect at least some differences in techniques between surgeons. This would require adjusting analyses for each surgeon, which would greatly increase the required sample size. We hypothesize that the more optimal the surgical resection, and the more optimal the intraoperative margin assessment, the better the outcome for patients with “inadequate”

margins. This would be seen as a lack of significant difference in outcome between patients with adequate and inadequate margins. We speculate that the degree of margin “inadequacy” was underestimated in the studies by Chen, Loree, and Garzino, which is reflected as significantly poorer outcomes for these patients.²⁸⁻³⁰ Testing this hypothesis requires a well-designed multicenter study, ideally limited to one anatomic site, which would be adequately powered to adjust for the many anticipated confounders.

Importantly, there is no accepted standard method for margin assessment. Our practice is to perform intraoperative margin surveillance and procure supplemental tissues to address close margins. We advocate that the resection margin surveillance should be “specimen driven”. The surgeon personally hands-off the specimen to the pathologist, and participates in specimen mapping. The pathologist cuts into the specimen at 5-10 mm intervals perpendicular to the resection margin plane. This gross assessment yields important preliminary information. The surgeon may elect to return to the defect at this time to harvest more tissue based on the gross examination, while the slides are being processed. This is followed by microscopic examination which further refines the information.

g. Human Papillomavirus (HPV)

Increasing incidence of HPV-associated HNSCC has led to shifts in overall patient demographics. The annual percentage increase for the incidence of tonsil/tongue base SCC is + 3.0% ($p < 0.05$).³⁴ A four-fold increased incidence of tonsillar SCC is observed for women (1945 to 1994), as compared to the 1.3 fold increase for men.³⁵ These studies are indirect evidence of the impact of HPV on HNSCC carcinogenesis. The mean age of diagnosis for patients with known HPV+HNSCC is younger than for patients with HPV negative tumors.³⁶ Numerous studies have demonstrated a strong association with HPV16 and oropharyngeal SCC, especially tonsillar SCC. Table 4 summarizes 23 studies of oropharyngeal SCC (OPSCC) and HPV, published from 2000 to 2007; the HPV detection rates range from 13% to 82%.³⁷⁻⁵⁹ Histologically, HPV+ SCC tend to be basaloid, and nonkeratinizing, however the keratinizing phenotype may also be associated with HPV.

The clinical and therapeutic importance of HPV-driven carcinogenesis relates to the observation that patients with HPV+HNSCC have better outcome than patients with tobacco-mediated HNSCC carcinogenesis. Furniss demonstrated improved survival for patients with HPV+ OPSCC (Hazard ratios of 0.4 and 0.5 for serum and tumor data, respectively).⁵⁶ This improvement is specifically associated with *productive* HPV infection. Weinberger demonstrated dramatically improved outcome when patients were stratified according to HPV viral

load plus p16 status, as compared to classification by HPV status alone.⁵⁴ High HPV copy number plus p16 overexpression is associated with 5-year overall survival of 75%, as compared to 15% for HPV negative cases, or 13% for cases with low HPV copy number and limited p16 expression (Hazard ratio 5.26). One could argue that direct measurement of HPV becomes irrelevant, and p16 alone may be a sufficient prognosticator. Fischer recently demonstrated 5-year overall survival rates for patients with p16+ OPSCC of 57.1% (95% CI: 37%, 73%) as compared to 26.8% (95% CI: 15%, 41%) for p16 negative OPSCC (based on 5% nuclear expression cut-off).⁶⁰

Overexpression of p16, a cell-cycle checkpoint regulator which inhibits cyclin-dependent kinase, has emerged as an important surrogate marker of productive HPV infection in OPSCC. The mechanism of p16 overexpression relates to HPV E7 protein, which is formed during productive infection. E7 binds and inactivates Rb protein, which leads to escape from cell cycle G1 arrest and S-phase entry. The overexpression of p16 is the result of loss of feedback inhibition following Rb inactivation.

In response to the original question, how can the surgical pathologist utilize immunohistochemical (IHC) p16 expression to guide future therapeutic planning? What is the sensitivity and specificity of p16 expression by IHC as compared to the gold standard of reverse-transcription polymerase chain reaction (RT-PCR)? It is important to emphasize that the presence of HPV DNA alone, as determined by PCR or in-situ hybridization (ISH) is insufficient to confirm productive infection. What cut-offs should be applied for p16 to deem a carcinoma HPV positive? Most researchers agree that *nuclear* p16 expression is required, however the cut-off for nuclear expression varies between studies and has been as low as 5%. The sensitivity and specificity for nuclear tumor p16 expression as a surrogate biomarker for HPV is 69% (95% CI 61%, 75%) and 90% (95% CI 81%, 95%).^{51,61-}

64

As patients with HPV-mediated cancers have a better prognosis, are they being over-treated by current protocols? Can they be offered less aggressive therapy? The treatment goal would be to decrease the risk of treatment-related toxicities while not compromising outcome. To the best of our knowledge, clinical trials designed to offer less intense treatment (“deintensification”) to patients with HPV-induced HNSCC, are still in the planning phases. The AJCC staging recommendation to include the reporting of HPV status speaks to the inevitability that this biomarker will become a very important stratifier for treatment planning.

References

1. American Joint Committee on Cancer – Cancer Staging Manual, Seventh Edition, 2010, Springer.
2. Yuen AP, Chow TL, Cheung WY, et al: Prospective randomized study of selective neck dissection versus observation for N0 Neck of early tongue carcinoma. *Head and Neck* DOI: 10.1002/hed.21033.
3. Fakih AR, Rao RS, Borges AM, Patel AR: Elective versus therapeutic neck dissection in squamous carcinoma of tongue a prospective randomized trial *Am J Surg* 1989; 158: 309-313.
4. Fukano H, Matsuura H, Hasegawa Y, Nakamura S: Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. *Head and Neck* 1997; 19: 205-210.
5. Sporo A, Weinstein G, Challian A, et al: Multivariate predictors of occult neck metastasis in early oral tongue cancer. *Otolaryngol Head Neck Surg* 2004; 131: 472-476.
6. An S, Jung EJ, Lee M, et al: Factors related to regional recurrence in early stage squamous cell carcinoma of the oral tongue. *Clin Exp Otorhinolaryngol* 2008; 1: 166-170.
7. Mohit-Tabatabai MA, Sobel HJ, Rush BF, Mashberg A: Relation of thickness of floor of mouth stage I and II cancers to regional metastasis. *Am J Surg* 1986; 152: 351-353.
8. Suzuki M, Suzuki T, Asai M, et al: Clinicopathologic factors related to cervical lymph node metastasis in a patient with carcinoma of the oral floor. *Acta Oto Laryngol* 2007; 127: 129-135.
9. Wallwork BD, Anderson SR, Coman WB: Squamous cell carcinoma of the floor of the mouth: tumor thickness and the rate of cervical metastasis. *ANZ J Surg* 2007; 77: 761-764.
10. Sessions DG, Spector GJ, Lenox J, et al: Analysis of treatment results for oral tongue cancer. *Laryngoscope* 2002; 112: 616-625.
11. Anneroth G, Batsakis J, Luna M: Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinoma." *Scan J Dent Res* 1987; 95:229-249
12. Bryne M, Koppang HS, Lilleng R, et al: New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. *J Oral Pathol Med* 1989; 18:432-437.
13. Bryne M, Koppang HS, Lilleng R, Kjaerheim A: Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. *J Pathol* 1992; 166:375-381.
14. Bryne M, Jenssen N, Boysen M: Histologic grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. *Virch Archiv* 1995; 427: 277-281.

15. Bundgaard T, Rossen K, Henriksen SD, et al: Histologic parameters in the evaluation of T1 squamous cell carcinomas of the oral cavity. *Head Neck* 2002;24: 656-660.
16. Jakobsson PA, Eneroth CM, Killander D, et al: Histologic classification and grading of malignancy in carcinoma of the larynx. *Acta Radiol Ther Phys Biol* 1973; 12: 1-8.
17. Odell EW, Jani P, Sherriff M, et al: The prognostic value of individual histologic grading parameters in small lingual squamous cell carcinomas. The importance of the pattern of invasion. *Cancer* 1994; 74: 789-794.
18. Po WYA, Lam KY, Lam LK, et al: Prognostic factors of clinically stage I and II oral tongue carcinoma. A comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. *Head Neck* 2002; 24: 513-520.
19. Sawair FA, Irwin CR, Gordon DJ, et al: Invasive front grading: reliability and usefulness in the management of oral squamous cell carcinoma. *J Oral Pathol Med* 2003; 32: 1-9.
20. Warburton G, Nikitakis NG, Roberson P, et al: Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. *J Oral Maxillofac Surg* 2007; 65: 475-484.
21. Fagan JJ, Collins B, Barnes L, et al: Perineural invasion in squamous cell carcinoma of the head and neck. *Arch Otolaryngol Head Neck Surg* 1998; 124: 637-640.
22. Rahima B, Shingaki S, Nagata M, Saito C: Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2004; 97: 423-431.
23. Sethi S, Lu M, Kapke A, et al: Patient and tumor factors at diagnosis in a multi-ethnic primary head and neck squamous cell carcinoma cohort. *J Surg Oncol* 2009; 99: 104-108.
24. McMahon J, O'Brien CJO, Pathak I, et al: Influence of condition of surgical margins on local recurrence and disease-specific survival in oral and oropharyngeal cancer. *Bri J Oral and Maxillofacial Surg* 2003; 41: 224-231.
25. Brandwein-Gensler M, Lewis C, Lee B, et al: Oral Squamous Cell Carcinoma: Histological risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. *Am J Surg Pathol* 2005; 20:167-178.
26. Brandwein-Gensler M, Smith RV, Wang B, et al: Validation and Reproducibility of the Histological Risk Model in a New Patient Cohort with Head and Neck Squamous Cell Carcinoma. Under consideration.

27. Byers RM, Bland KI, Borlase B, Luna M: The prognostic and therapeutic value of frozen section determination in the surgical treatment of squamous cell carcinoma of the head and neck. *Am J Surg* 1978; 136:525-528.
28. Chen TY, Edmrich LJ, Driscoll DL: The clinical significance of pathological findings in surgically resected margins of the primary tumor in head and neck carcinoma. *Int J Rad Oncol Biol Phys* 1987; 13: 833-837.
29. Loree TR, Strong EW: Significance of positive margins in oral cavity squamous carcinoma. *Am J Surg* 1990; 160: 410-414,
30. Garzino-Demo P, Dell'Acqua A, Dalmaso P, et al: Clinicopathologic parameters and outcome of 245 patients operated for oral squamous cell carcinoma. *J Cranio-Maxillofacial Surg* 2006; 34: 344-350.
31. El-Husseiny, Kandil A, Jamshed A, et al: Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors. *Brit J Oral Maxillofac Surg* 2000; 38:193-199.
32. Amaral TMP, Freire ARS, Carvalho AL, et al: Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of mouth. *Oral Oncol* 2004; 40: 780-786.
33. Weijers M, Snow GB, Bezemer DP, et al: The status of the deep surgical margins in tongue and floor of mouth squamous cell carcinoma and risk of local recurrence: an analysis of 68 patients. *Int J Oral Maxillofac Surg* 2004; 33: 146-149.
34. Ryerson AB, Peters ES, Coughlin SS, et al: Burden of potentially Human Papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. *Cancer* 2008;113: 2901-2909.
35. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ: Changing patterns of tonsillar Squamous cell carcinoma in the United States. *Cancer Causes and Control* 2000; 11: 489-495.
36. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J Clin Oncol* 2008; 26: 612-619.
37. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between HPV and a subset of head and neck cancers. *J Natl Cancer Inst.* 2000, 92:709-720.
38. Mellin H, Friesland S, Lewensohn R, et al: HPV DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. *Int J Cancer.* 2000,89:300-304.

39. Schwartz SR, Yueh B, McDougall JK, *et al*: HPV infection and survival in oral squamous cell cancer: a population-based study. *Otolaryngol Head Neck Surg.* 2001;125:1-9.
40. Mork J, Lie AK, Glattre E, *et al*: HPV infection as a risk factor for squamous-cell carcinoma of the head and neck. *N Engl J Med.* 2001; 344:1125-1131
41. Ringstrom E, Peters E, Hasegawa M, *et al*: HPV type 16 and squamous cell carcinoma of the head and neck. *Clin Cancer Res.* 2002,10:3187-3192.
42. Dahlstrom KR, Adler-Storthz K, *et al*: HPV type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. *Clin Cancer Res.* 2003; 9:2620-2626.
43. El-Mofty SK, Lu DW: Prevalence of HPV type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. *Am J Surg Pathol.* 2003; 11:1463-1470.
44. Herrero R, Castellsague X, Pawlita M, *et al*: HPV and oral cancer: the International Agency for Research on Cancer multicenter study. *J Natl Cancer Inst.* 2003; 95:1772-1783.
45. Begum S, Cao D, Gillison M, *et al*: Tissue distribution of HPV 16 DNA integration in patients with tonsillar carcinoma. *Clin Cancer Res.* 2005; 11:5694-5699.
46. Hansson BG, Rosenquist K, Antonsson A, *et al*: Strong association between infection with HPV and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. *Acta Otolaryngol.* 2005; 125:1337-1344.
47. Ibieta BR, Lizano M, Fras-Mendivil M, *et al*: HPV in oral squamous cell carcinoma in a Mexican population. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2005; 99:311-315.
48. Koppikar P, deVilliers EM, Mulherkar R.: Identification of HPV in tumors of the oral cavity in an Indian community. *Int J Cancer.* 2005; 113:946-950.
49. Kreimer AR, Clifford GM, Snijders PJ, *et al*: HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. *Int J Cancer.* 2005; 115:329-332.
50. Tachezy R, Klozar J, Salakova M, *et al*: HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. *Oral Dis.* 2005; 11:181-185.
51. El-Mofty SK, Patil S: HPV-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006; 101:339-345.

52. Licitra L, Perrone F, Bossi P, *et al*: High-risk HPV affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. *J Clin Oncol*. 2006; 24:5630-5636.
53. Nemes JA, Deli L, Nemes Z, Marton IJ: Expression of p16(INK4A), p53, and Rb proteins are independent from the presence of HPV genes in oral squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2006; 102:344-352.
54. Weinberger PM, Yu Z, Haffty BG, *et al*: Molecular classification identifies a subset of HPV-associated oropharyngeal cancers with favorable prognosis. *J Clin Oncol*. 2006; 24:736-747.
55. D'Souza G, Kreimer AR, Viscidi R, *et al*: Case-control study of HPV and oropharyngeal cancer. *N Engl J Med*. 2007; 356:1944-1956.
56. Furniss CS, McClean MD, Smith JF, *et al*: HPV 16 and head and neck squamous cell carcinoma. *Int J Cancer*. 2007; 120:2386-2392.
57. Pintos J, Black MJ, Sadeghi N, *et al*: HPV infection and oral cancer: A case-control study in Montreal, Canada. *Oral Oncol*. 2008; 44: 242-250.
58. Smith EM, Ritchie JM, Pawlita M, *et al*: HPV seropositivity and risks of head and neck cancer. *Int J Cancer*. 2007; 120:825-832.
59. Schlecht NF, Burk RD, Adrien L, *et al*: Gene expression profiles in HPV-infected head and neck cancer. *J Pathol*. 2007; 213:283-293.
60. Fischer CA, Zlobec I, Green E, *et al*: Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? *Int J Cancer* 2009 Aug 20 {Epub ahead of print}.
61. Wittekindt C, Gültekin E, Weissenborn SJ, *et al*: Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. *Adv Otorhinolaryngol*. 2005; 62:72-80.
62. Kim SH, Koo BS, Kang S, *et al*: HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. *Int J Cancer* 2007; 120: 1418-1425.
63. Charfi L, Jouffroy T, de Cremoux P, *et al*: Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome. *Cancer Lett*. 2008; 260:72-78.
64. Kuo KT, Hsiao CH, Lin CH, *et al*: The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome. *Mod Pathol*. 2008; 21:376-386.